MedTrace Logo

Sexual Quality of Life in Women During the First Year of Adjuvant Hormonal Treatment for Breast Cancer.

NCT04539587 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 106

Last updated 2025-02-13

No results posted yet for this study

Summary

Breast cancer is the most common cancer in women worldwide. Hormonal therapy is one of the major treatments for hormone receptor positive breast tumors. It is prescribed to 70% of breast cancer patients. Hormonal therapy can be responsible for sexual dysfunction induced by hormonal changes. Extended adjuvant hormonal therapy over 5 years increases these adverse effects.

According to the third "Plan Cancer" (2014-2019), sexual dysfunction prevention and screening must be systematic as an integral part of supportive care. Nevertheless, sexual quality of life remains too rarely considered.

In this study, the investigator propose to evaluate sexual quality of life of women less than 51 years old during the adjuvant endocrine therapy for localized breast cancer. The investigator also intend to collect the supportive measures or interventions used by women to overcome sexual dysfunction. Finally, this study aims to evaluate the need for sexual trouble specific management and acceptability of different methods.

This project is a hot topic as the interest for oncosexuality is growing, and the need for specific management is increasing with still insufficient access to specific care.

Conditions

Interventions

OTHER

Quality of life

The patient will receive the following questionnaires to be completed : EORTC QLQ-C30 EORTC QLQ-BR23 EORTC SHQ-C22

Sponsors & Collaborators

  • Institut du Cancer de Montpellier - Val d'Aurelle

    lead OTHER

Principal Investigators

  • Véronique D'HONDT, MD · Institut Régional du Cancer de Montpellier (ICM)

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-02
Primary Completion
2018-11-30
Completion
2019-10-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04539587 on ClinicalTrials.gov